1. Scrip
  2. >>R&D
  3. >>Clinical Trials

AbbVie’s Venclexta Fails In Combo AML Trial

Pfizer’s Daurismo May Benefit From Venclexta’s VIALE-C Setback

 
• By Sten Stovall

AbbVie’s Venclexta failed to show a significant improvement in the primary endpoint of overall survival in the Phase III VIALE-C for AML, but there was numerical improvement. Its setback is good news for Pfizer’s rival Daurismo, analysts said.

AML
Venclexta missed VIALE-C Phase III endpoints in acute myeloid leukemia • Source: Shutterstock

Prospects for AbbVie Inc.’s Venclexta (venetoclax) becoming a fully approved treatment for acute myeloid leukemia (AML) were thrown into doubt when the B-cell lymphoma-2 inhibitor failed to show a significant improvement in the primary endpoint of overall survival (OS) in the ongoing VIALE-C Phase III study, although it did demonstrate numerical improvement.

AbbVie on 28 February said that the VIALE-C trial evaluating Venclexta in combination with low-dose cytarabine (LDAC) versus LDAC in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

In Brief: Atai-Beckley Deal Marches On After Phase II Psychedelic Win

 
• By Manas Mishra

The psychedelic therapy firms pass a key condition for their planned merger after the antidepressant BPL-003 meets the main endpoints of a Phase IIb trial.

BerGenBio Plumps For Oncoinvent From Long List Of 50 Suitors

 
• By Kevin Grogan

The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.

In Brief: Opus Gears Up For FDA Filing In Presbyopia

 
• By Sushmita Panda

Data from a second pivotal trial support a filing in the US for Opus Genetics’ phentolamine ophthalmic solution, to treat presbyopia.

BlissBio Goes Solo On HER2-Targeting ADC After Eisai Exit

 
• By Dexter Jie Yan

BlissBio is to single-handedly move BB-1701, its eribulin-containing, HER2-targeting antibody-drug conjugate, into a global pivotal Phase II/III program for HER2-expressing, Enhertu-resistant breast cancer.

More from R&D

Watch This Space: Miltenyi‘s ‘Brain-To-Vein,’ Point-Of-Care CAR-T Efforts In India

 
• By Anju Ghangurde

From a letter of intent with BIRAC sealed at BIO 2025 to supporting Immuneel’s CAR-T efforts and a study for point-of-care manufactured anti-CD19 CAR-T cell therapy, Miltenyi Biotec is moving on multiple fronts in India. The German group also expects to advance its own CAR-T candidates.

Decentralized Trials Enroll Larger, More Diverse Patient Populations

 
• By Alaric DeArment

A new study by Tufts CSDD performed a deep dive into use of decentralized clinical trial techniques, but one of the study’s authors said DCTs have been dialed back.

Protagonist Hopes To Come From Behind In Obesity With Oral Triple Agonist

 
• By Jessica Merrill

The company announced plans to move an oral GLP-1/GIP/GCG receptor agonist peptide into clinical development for obesity in 2026.